<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  <head>
    <meta charset="utf-8" />
<meta property="og:site_name" content="Vertex Pharmaceuticals" />
<meta property="og:type" content="website" />
<meta property="og:url" content="https://investors.vrtx.com/press-releases" />
<meta property="og:title" content="Press Releases | Vertex Pharmaceuticals" />
<meta property="og:description" content="The Investor Relations website contains information about Vertex Pharmaceuticals&#039;s business for stockholders, potential investors, and financial analysts." />
<meta name="Generator" content="Drupal 10 (https://www.drupal.org)" />
<meta name="MobileOptimized" content="width" />
<meta name="HandheldFriendly" content="true" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<link rel="icon" href="/sites/g/files/knoqqb74911/files/favicon.ico" type="image/vnd.microsoft.icon" />
<link rel="alternate" hreflang="en" href="https://investors.vrtx.com/press-releases" />
<link rel="canonical" href="https://investors.vrtx.com/press-releases" />
<link rel="shortlink" href="https://investors.vrtx.com/node/5816" />

    <title>Press Releases | Vertex Pharmaceuticals</title>
    <link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_1HvT-90as-e3CXVWo_1w4S2XTy309NZf7XoB6NbSpLQ.css?delta=0&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_Irk1fXP27BWbV6Mh5txGirKi1dfzWYXgLu8LcVhc-H0.css?delta=1&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Arimo:400,400italic,700,300italic" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Poiret+One" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Josefin+Slab:400,700,600,300" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_WF_WjdFnydexFLH-q6EV4RnXpbWPAYGc92V0TcW0t5g.css?delta=5&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="print" href="/sites/g/files/knoqqb74911/files/css/css_BafFCdsxiUI1wldlRvpIN5iLHxcBJGqNdV_v3x4wwU4.css?delta=6&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_rnf9BGrG97ZF8sypxyVluZjd7arGQ8x7Upxx8ceBe3g.css?delta=7&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />

    <script src="/core/assets/vendor/modernizr/modernizr.min.js?v=3.11.7"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_zcZJg2ceexb8o86eQ2I6FQDMa0-CSF5vKxCHlcH4HzE.js?scope=header&amp;delta=1&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>

    <!-- OneTrust Cookies Consent Notice start for vrtx.com -->
<script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" data-document-language="true" type="text/javascript" charset="UTF-8" data-domain-script="55293c39-90c9-481e-be5a-a536e7236802" ></script>
<script type="text/javascript">
function OptanonWrapper() {
    var countryCode = OneTrust.getGeolocationData().country
    dataLayer.push({event:"GACountry", OneTrustCountryCode: countryCode})
}
</script>
<!-- OneTrust Cookies Consent Notice end for vrtx.com -->

<!-- Google Analytics Code -->
<script type="text/plain" class="optanon-category-C0002">
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
    m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})
  (window,document,'script','//www.google-analytics.com/analytics.js','ga');
                                
  ga('create', 'UA-709045-2', 'auto');
  ga('send', 'pageview');
</script>

<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-60HPP96Z4B" type="text/plain" class="optanon-category-C0002"></script>
<script type="text/plain" class="optanon-category-C0002"> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-60HPP96Z4B'); </script> 


<!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='https://analytics.imirwin.com/js/container_rVlDBFll.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->
  </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-landing-page nir-node--5816 path-node page-node-type-nir-landing-page">
    <div id="skip">
      <a class="visually-hidden focusable skip-link" href="#main-menu">
        Skip to main navigation
      </a>
    </div>
    
      <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas>
    

<a href="#skip-to-content" class="hide-txt">Skip to Content</a>

<div class="off-canvas-wrapper">

    <div class="off-canvas-wrapper-inner" data-off-canvas-wrapper>

        <div class="off-canvas position-left reveal-for-large" id="my-info" data-off-canvas data-position="left">
            <div class="row column">
                <span class="logo">
                  <br>
                  <a href="//www.vrtx.com/">
                  <!-- animated logo -->
                   <img class="logo-light" src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/white-vector.svg" alt="Vertex Pharmaceuticals">
                                        </a>
                  <br/>
                </span>

                <!-- nav -->
                <div class="row side-nav">
                    <div class="medium-8 medium-centered columns">
                        
    

<nav role="navigation" aria-labelledby="block-investorrelations-2-menu" class="block--system-menu-blockir block--system-menu-blockir--5816 block--sidebar-first--system-menu-block--ir block--sidebar-first--system-menu-block--ir--5816 block--e99e7083-5a42-4093-bf00-e1b8438402d1 block--e99e7083-5a42-4093-bf00-e1b8438402d1--5816 block block-menu navigation block-system-menublock menu--ir">
                        
    <h2 class="visually-hidden" id="block-investorrelations-2-menu">Investor Relations</h2>
    

                                            <ul data-block-uuid="e99e7083-5a42-4093-bf00-e1b8438402d1" class="vertical accordion-menu menu" data-accordion-menu>
                                        <li>
                <a href="/" target="" rel="" title="Main Investor Relations Page" data-drupal-link-system-path="&lt;front&gt;">Investors Home</a>
                            </li>
                                <li class="active-trail">
                <a href="/press-releases" target="" rel="" data-drupal-link-system-path="node/5816">News &amp; Events</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/press-releases" data-drupal-link-system-path="node/5816">Press Releases</a>
                            </li>
                                <li>
                <a href="/events-presentations" target="" rel="" data-drupal-link-system-path="node/24456">Events &amp; Presentations</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/stock-information" data-drupal-link-system-path="node/5916">Stock Information</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/stock-information" target="" rel="" data-drupal-link-system-path="node/5916">Quote &amp; Chart</a>
                            </li>
                                <li>
                <a href="/stock-information/historic-stock-lookup" data-drupal-link-system-path="node/5921">Historic Stock Lookup</a>
                            </li>
                                <li>
                <a href="/stock-information/investment-calculator" data-drupal-link-system-path="node/5926">Investment Calculator</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/stock-information/analyst-coverage" data-drupal-link-system-path="node/5896">Analyst Coverage</a>
                            </li>
                                <li>
                <a href="/financial-information/quarterly-results" target="" rel="" data-drupal-link-system-path="node/5986">Financial Information</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/financial-information/quarterly-results" data-drupal-link-system-path="node/5986">Quarterly Results</a>
                            </li>
                                <li>
                <a href="/financial-information/sec-filings" data-drupal-link-system-path="node/5876">SEC Filings</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Corporate Governance</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="http://www.vrtx.com/our-company/leadership">Leadership</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/our-company/leadership/#board-of-directors">Board of Directors</a>
                            </li>
                                <li>
                <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Governance Documents</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">Investor Resources</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">IR Contacts</a>
                            </li>
                                <li>
                <a href="/investor-faqs" target="" rel="" data-drupal-link-system-path="node/5941">FAQs</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/medicines/our-approved-medicines">Approved Medicines</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/our-science/pipeline">Pipeline</a>
                            </li>
                                <li>
                <a href="/email-alerts" data-drupal-link-system-path="node/5946">Email Alerts</a>
                            </li>
                </ul>
    
                            </li>
                </ul>
    


    </nav>
<div id="block-stockquote-2" data-storage-id="node:31451:flexible_layout" class="block--market-data-block__stock-quote block--market-data-block__stock-quote--31451 block--sidebar-first--market-data-block__stock-quote block--sidebar-first--market-data-block__stock-quote--31451 block--b23b16fc-7147-4bf3-bd29-2d329f8920d5 block--b23b16fc-7147-4bf3-bd29-2d329f8920d5--31451 block block-nir-market-data-block block-market-data-block__stock-quote">
  
    
      <div class='text-center'>
    <div class="quote-wrapper">
        <h5 class="text-center"></h5>
        <table class="stock-qupte">
            <tbody>
                                                                                                                                            <tr>
                    <td>Price</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Change</td>
                    <td></td>
                </tr>
                                                </tbody>
        </table>
    </div>
</div>
<div class="stock-time">
     - </div>
  </div>

<div id="block-stockinfoattributionthomsonreuters" class="block--attribution-block__stock-info-attribution__thomson-reuters block--attribution-block__stock-info-attribution__thomson-reuters--31451 block--sidebar-first--attribution-block__stock-info-attribution__thomson-reuters block--sidebar-first--attribution-block__stock-info-attribution__thomson-reuters--31451 block--34dc1e1a-9db4-405e-8e35-49f1041b8bfc block--34dc1e1a-9db4-405e-8e35-49f1041b8bfc--31451 block block-nir-attribution-block block-attribution-block__stock-info-attribution__thomson-reuters">
  
    
      <p>
  Data Provided by Refinitiv. Delayed ~15m.</p>

  </div>

<div id="block-widgetstockchart" class="block--nir-stock-chart block--nir-stock-chart--31451 block--sidebar-first--nir-stock-chart block--sidebar-first--nir-stock-chart--31451 block--c72aa970-06ea-4045-b1b5-f20d0b0ba4f7 block--c72aa970-06ea-4045-b1b5-f20d0b0ba4f7--31451 block block-nir-stock-chart">
  
      <h2  id="block-nir-stock-chart">Nasdaq: VRTX</h2>
    
      
<img src="https://api.nasdaqomx.wallst.com/api/chart?display=mountain&symbol=VRTX.O-VRTX&scale=linear&duration=1yr&frequency=1dy&gridLine=n&bgColor=52247f&lineColor=ffffff&fillcolor=52247f|52247f&width=560&height=300&&amp;volume=0&amp;fontColor-C0=FFFFFF&amp;fontColor-C1=FFFFFF" width="560" height="300" ></img>

  </div>

                    </div>
                </div>

            </div>


                        <div class="stock text-center">
                  <div class="region region-sidebar-featured">
    <div id="block-shareholdertools-2" class="block--system-menu-blockshareholder-tools block--system-menu-blockshareholder-tools--31451 block--sidebar-featured--system-menu-block--shareholder-tools block--sidebar-featured--system-menu-block--shareholder-tools--31451 block--4121c46a-4fb3-40cf-a26e-3dc466a9248c block--4121c46a-4fb3-40cf-a26e-3dc466a9248c--31451 block block-system block-system-menu-blockshareholder-tools gcs-sidebar-block">
  
    
                    <ul data-block-uuid="4121c46a-4fb3-40cf-a26e-3dc466a9248c" class="tools">
          
                                              
        <li class="side-menu__item">
                    <a href="/email-alerts" title="Email Alerts" class="glyph-icon flaticon-alarm-1" target="">
            <span class="fa-stack">
            
                               <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/notifications.svg" alt="">
                
            </span>
          </a>

                  </li>
      
                                              
        <li class="side-menu__item">
                    <a href="/rss-news-feeds" title="RSS News Feeds" class="glyph-icon flaticon-newspaper" target="">
            <span class="fa-stack">
            
                              <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/rss_feed.svg" alt="">

              
            </span>
          </a>

                  </li>
      
                                                
        <li class="side-menu__item">
                    <a href="/investor-feedback" title="Investor Feedback" class="glyph-icon flaticon-paper-plane" target="">
            <span class="fa-stack">
            
                              <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/email.svg" alt="">
              
            </span>
          </a>

                  </li>
          </ul>
  


  </div>

  </div>

            </div>
            




        </div> <!-- /off-canvas -->

        <div class="off-canvas-content"  id="skip-to-content" data-off-canvas-content>

            <div class="title-bar hide-for-large">
                <div class="title-bar-left">
                    <button class="menu-icon" type="button" data-open="my-info" aria-label="Menu button"></button>
                    <span class="title-bar-title"><!-- Menu --></span>
                </div>
                <span class="logo">
                  <a href="//www.vrtx.com/">
                    <!-- static logo -->
                    <img class="logo-light" src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/white-vector.svg" alt="Vertex Pharmaceuticals">
                                        </a>
                </span>
            </div>

            <div class="callout primary">
                <div class="row">
                    <h1 class="header-title">

                                            News & Events
                                        </h1>

                                    </div>
            </div>

            

            


                            <div id="ndq-content" class="row ndq-5816 inside-pages large-12 columns">
                    <h2 class="h2content-heading">

                                                    Press Releases
                                            </h2>



                      <div class="region region-content">
    <div id="block-nir-pid2172-websitenoticeblock" class="block--website-notice-block block--website-notice-block--5816 block--content--website-notice-block block--content--website-notice-block--5816 block--dd8b7d55-3418-4333-8560-aa0535832f20 block--dd8b7d55-3418-4333-8560-aa0535832f20--5816 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2172-content" class="block--system-main-block block--system-main-block--5816 block--content--system-main-block block--content--system-main-block--5816 block--32fb46b7-e82f-437f-b00f-4734f5697096 block--32fb46b7-e82f-437f-b00f-4734f5697096--5816 block block-system block-system-main-block">
  
    
      <article class="node node--type-nir_landing_page node--view-mode-full clearfix">
  
      <h1>
              Press Releases
          </h1>
    

  <div>
    
<div class="panel-display boxton clearfix " >

  <div class="container-fluid">
    <div class="row">
      <div class="columns large-12 radix-layouts-content panel-panel">
        <div class="panel-panel-inner">
          <div class="block-region-contentmain">
<div class="block--search-form block--search-form--5816 block--contentmain--search-form block--contentmain--search-form--5816 block--69c1a507-53a5-47e3-8700-d9cecb7ecae7 block--69c1a507-53a5-47e3-8700-d9cecb7ecae7--5816 block block-nir-search block-search-form">
  
    
      <form data-block-uuid="69c1a507-53a5-47e3-8700-d9cecb7ecae7" action="/search" method="get" accept-charset="UTF-8">
  <div class="js-form-item form-item js-form-type-search form-item-query js-form-item-query form-no-label">
        <input type="search" name="query" size="60" maxlength="128" placeholder="What are you looking for today?" class="form-search required" required="required" aria-required="true" />

        </div>
<input type="hidden" name="f[0]" value="type:nir_news" />
<input type="submit" name="op" value="Search" class="button button--primary js-form-submit form-submit" />

</form>

  </div>

<div class="views-element-container block--views-blockwidget-news-table block--views-blockwidget-news-table--5816 block--contentmain--views-block--widget-news-table block--contentmain--views-block--widget-news-table--5816 block--c9e9f210-6659-4313-bbd1-f20963e32837 block--c9e9f210-6659-4313-bbd1-f20963e32837--5816 block block-views block-views-blockwidget-news-table">
  
    
      <div data-block-uuid="c9e9f210-6659-4313-bbd1-f20963e32837"><div class="view view-widget-news view-id-widget_news view-display-id-table js-view-dom-id-4d0cc7b31c7ab843e494597b0ddcd1f25e29135fb7c4a24fd0783ee4d0824d32">
  
    
      
      <div class="view-content">
      <table class="nirtable views-table views-view-table cols-3 collapse-table">
        <thead>
      <tr>
                                                  <th id="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date" scope="col"><a href="?items_per_page_toggle=1&amp;page=8&amp;order=field_nir_news_date&amp;sort=asc" title="sort by Date">Date</a></th>
                                                  <th id="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title" scope="col"><a href="?items_per_page_toggle=1&amp;page=8&amp;order=field_nir_news_title&amp;sort=asc" title="sort by Title and Summary">Title and Summary</a></th>
                                                  <th id="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format" scope="col">Additional Formats</th>
              </tr>
    </thead>
    <tbody>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-10-07T20:53:00Z" timezone="America/New_York" class="datetime">Oct 7, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/supplemental-new-drug-application-use-kalydecor-ivacaftor-people" hreflang="en">Supplemental New Drug Application for Use of KALYDECO® (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older who have One of 23 Residual Function Mutations Accepted for Priority Review by U.S. FDA</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -More than 1,500 people with CF are ages two and older and have one of these 23 residual function mutations in the U.S.- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/supplemental-new-drug-application-use-kalydecor-ivacaftor-people" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/84adaf88-1f65-4fce-aded-cf7ab1042930" type="application/pdf" title="VRTX_News_2015_10_7_General.pdf">Supplemental New Drug Application for Use of KALYDECO&#174; (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older who have One of 23 Residual Function Mutations Accepted for Priority Review by U.S. FDA</a></span><span class="filesize"> 22.5 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-09-25T11:17:00Z" timezone="America/New_York" class="datetime">Sep 25, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-chmp-positive-opinions-orkambitm" hreflang="en">Vertex Receives CHMP Positive Opinions for ORKAMBI™ (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) in the European Union</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -CHMP recommends Marketing Authorization for lumacaftor in combination with ivacaftor for people with cystic fibrosis ages 12 and older with two copies of the F508del mutation- -CHMP recommends Marketing Authorization for ivacaftor for children with cystic fibrosis ages 2 to 5 with 9 gating
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-chmp-positive-opinions-orkambitm" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/8163ecf3-05ca-4946-8841-110e34c5c8c4" type="application/pdf" title="VRTX_News_2015_9_25_General.pdf">Vertex Receives CHMP Positive Opinions for ORKAMBI&#8482; (lumacaftor/ivacaftor) and KALYDECO&#174; (ivacaftor) in the European Union</a></span><span class="filesize"> 16.5 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-09-08T20:01:00Z" timezone="America/New_York" class="datetime">Sep 8, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-morgan-stanley-healthcare-conference-september-16" hreflang="en">Vertex to Present at the Morgan Stanley Healthcare Conference on September 16</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Morgan Stanley Healthcare Conference in New York, NY on Wednesday, September 16 th at 11:40 a.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-morgan-stanley-healthcare-conference-september-16" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/b2c14314-001b-476a-b709-b516c70680e8" type="application/pdf" title="VRTX_News_2015_9_8_Webcasts.pdf">Vertex to Present at the Morgan Stanley Healthcare Conference on September 16</a></span><span class="filesize"> 10.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-08-19T18:35:00Z" timezone="America/New_York" class="datetime">Aug 19, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-awards-two-boston-public-high-school-students-vertex" hreflang="en">Vertex Awards Two Boston Public High School Students the Vertex Science Leaders Scholarship to the University of Massachusetts</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  Hosts August 19 th back to school event with Bottom Line for 200+ first-generation college students BOSTON --(BUSINESS WIRE)-- Vertex and the University of Massachusetts (UMass) today announced the recipients of the annual Vertex Science Leaders Scholarship , a four-year scholarship to pursue their
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-awards-two-boston-public-high-school-students-vertex" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/216b8723-ed9c-421a-a1df-fb803b83e740" type="application/pdf" title="VRTX_News_2015_8_19_General.pdf">Vertex Awards Two Boston Public High School Students the Vertex Science Leaders Scholarship to the University of Massachusetts</a></span><span class="filesize"> 24.3 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-07-29T20:01:00Z" timezone="America/New_York" class="datetime">Jul 29, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-second-quarter-2015-financial-results" hreflang="en">Vertex Reports Second Quarter 2015 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Second quarter 2015 total revenues of $166 million , including net product revenues of approximately $155 million for KALYDECO ® (ivacaftor) in cystic fibrosis- -Vertex increases guidance for total 2015 KALYDECO net revenues; now expects KALYDECO revenues of $575 to $590 million - -ORKAMBI™
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-second-quarter-2015-financial-results" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/ae1a0e22-47cd-497b-a533-be116b0e57b4" type="application/pdf" title="VRTX_News_2015_7_29_General.pdf">Vertex Reports Second Quarter 2015 Financial Results</a></span><span class="filesize"> 66 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-07-14T13:00:00Z" timezone="America/New_York" class="datetime">Jul 14, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-second-quarter-2015-financial-results-july-29" hreflang="en">Vertex to Announce Second Quarter 2015 Financial Results on July 29</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2015 financial results on Wednesday, July 29, 2015 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-second-quarter-2015-financial-results-july-29" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/b8c0291f-1000-4b75-998a-6554cae95ad0" type="application/pdf" title="VRTX_News_2015_7_14_Webcasts.pdf">Vertex to Announce Second Quarter 2015 Financial Results on July 29</a></span><span class="filesize"> 10.3 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-07-02T17:46:00Z" timezone="America/New_York" class="datetime">Jul 2, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/adding-multimedia-fda-approves-orkambitm-lumacaftorivacaftor" hreflang="en">ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Approximately 8,500 people in the U.S. are ages 12 and older and have two copies of the F508del mutation, the most common genetic form of the disease- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/adding-multimedia-fda-approves-orkambitm-lumacaftorivacaftor" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/6a42f6b4-41c7-4be9-8d61-aaedc6798f15" type="application/pdf" title="VRTX_News_2015_7_2_General.pdf">ADDING MULTIMEDIA FDA Approves ORKAMBI&#8482; (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation</a></span><span class="filesize"> 29.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-07-02T17:46:00Z" timezone="America/New_York" class="datetime">Jul 2, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/fda-approves-orkambitm-lumacaftorivacaftor-first-medicine-treat" hreflang="en">FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Approximately 8,500 people in the U.S. are ages 12 and older and have two copies of the F508del mutation, the most common genetic form of the disease- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/fda-approves-orkambitm-lumacaftorivacaftor-first-medicine-treat" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/6a42f6b4-41c7-4be9-8d61-aaedc6798f15" type="application/pdf" title="VRTX_News_2015_7_2_General.pdf">FDA Approves ORKAMBI&#8482; (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation</a></span><span class="filesize"> 29.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-06-18T20:01:00Z" timezone="America/New_York" class="datetime">Jun 18, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/sangeeta-n-bhatia-md-phd-joins-vertex-board-directors" hreflang="en">Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Sangeeta N. Bhatia , M.D., Ph.D., joined its board of directors as an independent director. Dr. Bhatia was elected to serve a three-year term ending in 2018. &quot; Dr.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/sangeeta-n-bhatia-md-phd-joins-vertex-board-directors" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/78ad0ca0-9cf7-479b-a80d-b0069ce1543a" type="application/pdf" title="VRTX_News_2015_6_18_General.pdf">Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors</a></span><span class="filesize"> 11.7 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-06-11T13:00:00Z" timezone="America/New_York" class="datetime">Jun 11, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-data-presentations-european-cystic-fibrosis" hreflang="en">Vertex Announces Data Presentations at European Cystic Fibrosis Society (ECFS) Conference</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Analysis from TRAFFIC and TRANSPORT extension study of lumacaftor in combination with ivacaftor showed that improvements in lung function and other measures of disease were maintained through 48 weeks in people with cystic fibrosis who have two copies of the F508del mutation- BRUSSELS --(BUSINESS
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-data-presentations-european-cystic-fibrosis" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/0dc66b3b-8ac1-4eee-b93f-0f225c1c4253" type="application/pdf" title="VRTX_News_2015_6_11_General.pdf">Vertex Announces Data Presentations at European Cystic Fibrosis Society (ECFS) Conference</a></span><span class="filesize"> 19.3 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-06-04T20:01:00Z" timezone="America/New_York" class="datetime">Jun 4, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-and-parion-sciences-establish-collaboration-develop" hreflang="en">Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -ENaC inhibition aims to restore or improve hydration of cell surfaces in the lungs to improve lung function- -Parion to receive $80 million up-front payment with potential for additional development and regulatory milestones and royalty payments- BOSTON &amp;amp; DURHAM, N.C.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-and-parion-sciences-establish-collaboration-develop" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/442638d3-9618-406e-b751-e84ad5597341" type="application/pdf" title="VRTX_News_2015_6_4_General.pdf">Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases</a></span><span class="filesize"> 22.6 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-06-03T20:01:00Z" timezone="America/New_York" class="datetime">Jun 3, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-goldman-sachs-healthcare-conference-june-11" hreflang="en">Vertex to Present at the Goldman Sachs Healthcare Conference on June 11</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Goldman Sachs Healthcare Conference in Rancho Palos Verdes, CA on Thursday, June 11 th at 12:20 p.m. ET ( 9:20 a.m. PT ).
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-goldman-sachs-healthcare-conference-june-11" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/7dcd6d85-14b2-49ef-b1e7-46fabfafbc0c" type="application/pdf" title="VRTX_News_2015_6_3_Webcasts.pdf">Vertex to Present at the Goldman Sachs Healthcare Conference on June 11</a></span><span class="filesize"> 10.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-05-17T17:32:00Z" timezone="America/New_York" class="datetime">May 17, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/new-england-journal-medicine-publishes-data-two-phase-3-studies" hreflang="en">New England Journal of Medicine Publishes Data from Two Phase 3 Studies of ORKAMBITM (lumacaftor/ivacaftor) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the  New England Journal of Medicine (NEJM)  published data from the two Phase 3 studies of ORKAMBI TM (lumacaftor/ivacaftor), an investigational medicine designed to treat the underlying cause of
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/new-england-journal-medicine-publishes-data-two-phase-3-studies" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/7362a9e5-e8d3-4c4b-b7d8-3e89c9a7397c" type="application/pdf" title="VRTX_News_2015_5_17_General.pdf">New England Journal of Medicine Publishes Data from Two Phase 3 Studies of ORKAMBITM (lumacaftor/ivacaftor) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation</a></span><span class="filesize"> 16.9 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-05-13T20:01:00Z" timezone="America/New_York" class="datetime">May 13, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-ubs-healthcare-conference-may-19" hreflang="en">Vertex to Present at the UBS Healthcare Conference on May 19</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jeffrey Leiden , M.D., Ph.D., Chairman, President &amp;amp; CEO of Vertex will present at the UBS Healthcare Conference in New York, NY on Tuesday, May 19 th at 11:00 a.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-ubs-healthcare-conference-may-19" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/00a103d0-31a8-47be-abf9-8a8707e5e263" type="application/pdf" title="VRTX_News_2015_5_13_Webcasts.pdf">Vertex to Present at the UBS Healthcare Conference on May 19</a></span><span class="filesize"> 9.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-05-12T20:15:00Z" timezone="America/New_York" class="datetime">May 12, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/food-and-drug-administration-advisory-panel-voted-12-1-recommend" hreflang="en">Food and Drug Administration Advisory Panel Voted 12 to 1 to Recommend Approval of ORKAMBI™ (lumacaftor/ivacaftor) to Treat People with Cystic Fibrosis Ages 12 and Older Who Have Two Copies of the F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - FDA decision expected by July 5, 2015 PDUFA date- -Approximately 8,500 people with cystic fibrosis in the U.S. have two copies of the F508del mutation and are ages 12 and older- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/food-and-drug-administration-advisory-panel-voted-12-1-recommend" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/860ee053-1576-47b6-863d-845f48cd9e90" type="application/pdf" title="VRTX_News_2015_5_12_General.pdf">Food and Drug Administration Advisory Panel Voted 12 to 1 to Recommend Approval of ORKAMBI&#8482; (lumacaftor/ivacaftor) to Treat People with Cystic Fibrosis Ages 12 and Older Who Have Two Copies of the F508del Mutation</a></span><span class="filesize"> 15.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-04-29T20:01:00Z" timezone="America/New_York" class="datetime">Apr 29, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-first-quarter-2015-financial-results" hreflang="en">Vertex Reports First Quarter 2015 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -First quarter 2015 total revenues of $139 million , including net product revenues of $130 million for KALYDECO ® (ivacaftor) in cystic fibrosis- -Cash, cash equivalents and marketable securities of approximately $1.2 billion on March 31, 2015 - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-first-quarter-2015-financial-results" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/8aa994a0-7e47-44a7-b29f-13722cbc065d" type="application/pdf" title="VRTX_News_2015_4_29_General.pdf">Vertex Reports First Quarter 2015 Financial Results</a></span><span class="filesize"> 54.6 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-04-09T20:01:00Z" timezone="America/New_York" class="datetime">Apr 9, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-first-quarter-2015-financial-results-april-29" hreflang="en">Vertex to Announce First Quarter 2015 Financial Results on April 29</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2015 financial results on Wednesday, April 29, 2015 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-first-quarter-2015-financial-results-april-29" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/35ee9207-5a4a-4e24-8382-abc12b832d5e" type="application/pdf" title="VRTX_News_2015_4_9_Webcasts.pdf">Vertex to Announce First Quarter 2015 Financial Results on April 29</a></span><span class="filesize"> 9.3 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-03-23T11:45:00Z" timezone="America/New_York" class="datetime">Mar 23, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-data-12-week-phase-2-safety-study-vx-661" hreflang="en">Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -The combination was generally well tolerated and all patients completed 12 weeks of treatment- -Mean within-group absolute improvement from baseline in lung function of 4.4 (p=0.009) and 3.0 (p=0.026) percentage points at week 4 and through 12 weeks of treatment, respectively, in patients who
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-data-12-week-phase-2-safety-study-vx-661" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/200bd924-ef14-43e3-82ad-93cf92496054" type="application/pdf" title="VRTX_News_2015_3_23_General.pdf">Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation</a></span><span class="filesize"> 37.9 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-03-18T11:46:00Z" timezone="America/New_York" class="datetime">Mar 18, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-us-food-and-drug-administration-approval" hreflang="en">Vertex Receives U.S. Food and Drug Administration Approval of KALYDECO® (ivacaftor) for Children with Cystic Fibrosis Ages 2 to 5 who have Specific Mutations in the CFTR Gene</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) approved KALYDECO ® for use in children ages 2 to 5 with cystic fibrosis (CF) who have one of 10 mutations in the cystic fibrosis transmembrane conductance
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-us-food-and-drug-administration-approval" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/7dd21f1e-3e58-4439-b23a-4c00e76b3702" type="application/pdf" title="VRTX_News_2015_3_18_General.pdf">Vertex Receives U.S. Food and Drug Administration Approval of KALYDECO&#174; (ivacaftor) for Children with Cystic Fibrosis Ages 2 to 5 who have Specific Mutations in the CFTR Gene</a></span><span class="filesize"> 26.8 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-02-11T21:05:00Z" timezone="America/New_York" class="datetime">Feb 11, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-upcoming-investor-conferences" hreflang="en">Vertex to Present at Upcoming Investor Conferences</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the RBC Capital Market Healthcare Conference in New York, NY on Tuesday, February 24 th at 11:30 a.m. ET . Vertex will also present at the Cowen and Company Healthcare Conference in
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-upcoming-investor-conferences" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/0ab36359-db09-4fe4-8867-44b21b505e3a" type="application/pdf" title="VRTX_News_2015_2_11_Webcasts.pdf">Vertex to Present at Upcoming Investor Conferences</a></span><span class="filesize"> 9.6 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-01-28T21:01:00Z" timezone="America/New_York" class="datetime">Jan 28, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2014-financial" hreflang="en">Vertex Reports Full-Year and Fourth Quarter 2014 Financial Results and Provides Guidance for 2015</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Full-year 2014 total revenues of $580 million , including net product revenues of $464 million for KALYDECO in cystic fibrosis- -Cash, cash equivalents and marketable securities of approximately $1.4 billion on December 31, 2014 - -Company expects total 2015 KALYDECO net revenues of $560 to $580
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2014-financial" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/243059e7-b5e9-4557-8909-2dfa0102efe2" type="application/pdf" title="VRTX_News_2015_1_28_General.pdf">Vertex Reports Full-Year and Fourth Quarter 2014 Financial Results and Provides Guidance for 2015</a></span><span class="filesize"> 80.2 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-01-12T01:49:00Z" timezone="America/New_York" class="datetime">Jan 11, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-outlines-2015-business-priorities-support-development" hreflang="en">Vertex Outlines 2015 Business Priorities to Support the Development, Approval and Launch of New Medicines for the Treatment of People with Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Priority Review granted for combination of lumacaftor and ivacaftor in people with cystic fibrosis ages 12 and older who have two copies of the F508del mutation; PDUFA date of July 5, 2015 - -More than 3,700 people with CF expected to be eligible to receive KALYDECO by end of 2015 supporting
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-outlines-2015-business-priorities-support-development" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/9ea3adf9-8478-45e1-a824-1802149712e4" type="application/pdf" title="VRTX_News_2015_1_11_General.pdf">Vertex Outlines 2015 Business Priorities to Support the Development, Approval and Launch of New Medicines for the Treatment of People with Cystic Fibrosis</a></span><span class="filesize"> 41.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2015-01-06T21:01:00Z" timezone="America/New_York" class="datetime">Jan 6, 2015</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-upcoming-presentation-jp-morgan-healthcare" hreflang="en">Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2014 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 33 rd Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 12:30 p.m. ET ( 9:30 a.m. PT ).
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-upcoming-presentation-jp-morgan-healthcare" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/eb596f84-52d7-4259-83dd-d5b1b726c3c1" type="application/pdf" title="VRTX_News_2015_1_6_Webcasts.pdf">Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2014 Financial Results</a></span><span class="filesize"> 9.9 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-12-29T20:11:00Z" timezone="America/New_York" class="datetime">Dec 29, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/us-food-and-drug-administration-approves-kalydecor-ivacaftor-use" hreflang="en">U.S. Food and Drug Administration Approves KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  --Approximately 500 people with cystic fibrosis ages 6 and older have the R117H mutation in the United States -- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/us-food-and-drug-administration-approves-kalydecor-ivacaftor-use" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/ff180de2-7da3-4d1c-a605-aa5bba5deb60" type="application/pdf" title="VRTX_News_2014_12_29_General.pdf">U.S. Food and Drug Administration Approves KALYDECO&#174; (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation</a></span><span class="filesize"> 26.9 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-12-15T14:00:00Z" timezone="America/New_York" class="datetime">Dec 15, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/david-altshuler-md-phd-joins-vertex-executive-vice-president" hreflang="en">David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief Scientific Officer</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated today announced that David Altshuler , M.D., Ph.D., will join the company as Executive Vice President, Global Research and Chief Scientific Officer. Dr. Altshuler was one of the four founding members of the Broad Institute of Harvard
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/david-altshuler-md-phd-joins-vertex-executive-vice-president" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/426b8a8a-d0bc-4234-84e5-80e782e9b864" type="application/pdf" title="VRTX_News_2014_12_15_General.pdf">David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief Scientific Officer</a></span><span class="filesize"> 14.6 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-11-20T21:01:00Z" timezone="America/New_York" class="datetime">Nov 20, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-deutsche-bank-biofest-december-2" hreflang="en">Vertex to Present at Deutsche Bank BioFEST on December 2</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Deutsche Bank BioFEST in Boston on December 2 at 8:45 a.m. ET . Management&#039;s remarks can be accessed live through Vertex&#039;s website at www.vrtx.com
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-deutsche-bank-biofest-december-2" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/7f597289-3f85-4a6f-a5d2-2b996d7d8730" type="application/pdf" title="VRTX_News_2014_11_20_Webcasts.pdf">Vertex to Present at Deutsche Bank BioFEST on December 2</a></span><span class="filesize"> 9.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-11-05T12:00:00Z" timezone="America/New_York" class="datetime">Nov 5, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-submits-applications-us-and-europe-approval-lumacaftor" hreflang="en">Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -U.S. submission includes request for Priority Review; Accelerated Assessment has been granted in the EU- -Approximately 8,500 people in the U.S. and 12,000 in Europe ages 12 and older have two copies of the F508del mutation- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-submits-applications-us-and-europe-approval-lumacaftor" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/1df389cb-7d81-47cb-a0f3-a928a6009cf1" type="application/pdf" title="VRTX_News_2014_11_5_General.pdf">Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation</a></span><span class="filesize"> 19.9 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-10-30T20:01:00Z" timezone="America/New_York" class="datetime">Oct 30, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-credit-suisse-healthcare-conference-november-11" hreflang="en">Vertex to Present at the Credit Suisse Healthcare Conference on November 11</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Credit Suisse Healthcare Conference on Tuesday, November 11 at 12:00 p.m. ET . Management&#039;s remarks can be accessed live through Vertex&#039;s website at www.vrtx.com in the
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-credit-suisse-healthcare-conference-november-11" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/82915a66-2a92-4fc5-a73b-8132417189a9" type="application/pdf" title="VRTX_News_2014_10_30_Webcasts.pdf">Vertex to Present at the Credit Suisse Healthcare Conference on November 11</a></span><span class="filesize"> 9.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-10-28T20:01:00Z" timezone="America/New_York" class="datetime">Oct 28, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-third-quarter-2014-financial-results" hreflang="en">Vertex Reports Third Quarter 2014 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended September 30, 2014 . Vertex reported total third quarter 2014 GAAP revenues of $179 million , including revenues of $127 million from KALYDECO ®
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-third-quarter-2014-financial-results" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/46b50cd0-e907-4491-ac59-8bd61778ac79" type="application/pdf" title="VRTX_News_2014_10_28_General.pdf">Vertex Reports Third Quarter 2014 Financial Results</a></span><span class="filesize"> 84.8 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-10-21T20:47:00Z" timezone="America/New_York" class="datetime">Oct 21, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/fda-advisory-committee-recommends-approval-kalydecor-ivacaftor" hreflang="en">FDA Advisory Committee Recommends Approval of KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration&#039;s Pulmonary Allergy Drugs Advisory Committee (PADAC) voted 13-2 to recommend approval of KALYDECO ® (ivacaftor) in people with cystic fibrosis (CF) ages 6 and
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/fda-advisory-committee-recommends-approval-kalydecor-ivacaftor" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/66133763-1c22-48fe-a702-6f7d92dc9a75" type="application/pdf" title="VRTX_News_2014_10_21_General.pdf">FDA Advisory Committee Recommends Approval of KALYDECO&#174; (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation</a></span><span class="filesize"> 26.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-10-14T20:01:00Z" timezone="America/New_York" class="datetime">Oct 14, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-third-quarter-2014-financial-results-october-28" hreflang="en">Vertex to Announce Third Quarter 2014 Financial Results on October 28</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2014 financial results on Tuesday, October 28, 2014 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-third-quarter-2014-financial-results-october-28" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/0ad3085d-c232-4b43-a612-527588a33285" type="application/pdf" title="VRTX_News_2014_10_14_Webcasts.pdf">Vertex to Announce Third Quarter 2014 Financial Results on October 28</a></span><span class="filesize"> 9.3 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-10-09T13:32:00Z" timezone="America/New_York" class="datetime">Oct 9, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reviews-recent-progress-and-announces-upcoming-milestones" hreflang="en">Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Data from across Vertex&#039;s cystic fibrosis research and development programs to be presented at the 28 th Annual North American Cystic Fibrosis Conference (NACFC) beginning today- -Interim analysis of rollover study following the Phase 3 TRAFFIC and TRANSPORT studies showed sustained improvements
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reviews-recent-progress-and-announces-upcoming-milestones" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/7ca4943b-d60a-4878-8d75-40026cb11b75" type="application/pdf" title="VRTX_News_2014_10_9_General.pdf">Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis</a></span><span class="filesize"> 96.1 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-09-08T13:00:00Z" timezone="America/New_York" class="datetime">Sep 8, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-upcoming-presentations-data-north-american" hreflang="en">Vertex Announces Upcoming Presentations of Data at North American Cystic Fibrosis Conference - October 9 to 11, 2014</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Data from Phase 3 TRAFFIC and TRANSPORT studies of lumacaftor in combination with ivacaftor and from Phase 3 rollover study of patients who completed TRAFFIC and TRANSPORT to be presented- -Other presentations include studies of ivacaftor in people with cystic fibrosis who have the R117H mutation,
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-upcoming-presentations-data-north-american" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/ec837477-149d-446e-ba65-22c34cd3eecb" type="application/pdf" title="VRTX_News_2014_9_8_General.pdf">Vertex Announces Upcoming Presentations of Data at North American Cystic Fibrosis Conference - October 9 to 11, 2014</a></span><span class="filesize"> 91.9 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-09-02T20:01:00Z" timezone="America/New_York" class="datetime">Sep 2, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-morgan-stanley-global-healthcare-conference" hreflang="en">Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 10</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10 at 8:35 a.m. ET . Management&#039;s remarks can be accessed live through Vertex&#039;s website at www.vrtx.com in
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-morgan-stanley-global-healthcare-conference" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/c63b53b9-3ba9-4707-b9a6-a3ec20b7d59c" type="application/pdf" title="VRTX_News_2014_9_2_Webcasts.pdf">Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 10</a></span><span class="filesize"> 9.2 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-07-31T20:18:00Z" timezone="America/New_York" class="datetime">Jul 31, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-european-approval-kalydecotm-ivacaftor-eight-non" hreflang="en">Vertex Receives European Approval for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -In Europe, approximately 250 people ages 6 and older have one of 8 additional gating mutations- -KALYDECO is the first medicine to treat the underlying cause of CF in people with specific non-G551D gating mutations- EYSINS, Switzerland --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-european-approval-kalydecotm-ivacaftor-eight-non" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/bedee8aa-95ba-4382-80c1-f258c37f85f0" type="application/pdf" title="VRTX_News_2014_7_31_General.pdf">Vertex Receives European Approval for KALYDECO&#8482; (ivacaftor) in Eight Non-G551D Gating Mutations</a></span><span class="filesize"> 27.9 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-07-29T20:01:00Z" timezone="America/New_York" class="datetime">Jul 29, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-second-quarter-2014-financial-results-and" hreflang="en">Vertex Reports Second Quarter 2014 Financial Results and Provides Updates on Key Research and Development Programs</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2014. Vertex reported total second quarter 2014 revenues of $138 million , including revenues of $113 million from KALYDECO ® (ivacaftor).
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-second-quarter-2014-financial-results-and" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/a8f27767-a1ad-4c06-b1c5-ee3bb796a7f1" type="application/pdf" title="VRTX_News_2014_7_29_General.pdf">Vertex Reports Second Quarter 2014 Financial Results and Provides Updates on Key Research and Development Programs</a></span><span class="filesize"> 89 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-07-14T20:01:00Z" timezone="America/New_York" class="datetime">Jul 14, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-second-quarter-2014-financial-results-july-29" hreflang="en">Vertex to Announce Second Quarter 2014 Financial Results on July 29</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2014 financial results on Tuesday, July 29, 2014 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-second-quarter-2014-financial-results-july-29" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/dbe152be-2fd9-4018-b7ff-a23457eb49f3" type="application/pdf" title="VRTX_News_2014_7_14_Webcasts.pdf">Vertex to Announce Second Quarter 2014 Financial Results on July 29</a></span><span class="filesize"> 9.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-07-10T12:00:00Z" timezone="America/New_York" class="datetime">Jul 10, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-retirement-peter-mueller-phd" hreflang="en">Vertex Announces Retirement of Peter Mueller, Ph.D.</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Peter Mueller , Ph.D., Executive Vice President of Global Research and Development and Chief Scientific Officer, will retire after more than 10 years with the company. Dr.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-retirement-peter-mueller-phd" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/1ee7b5c7-8df1-439b-b51e-647ccfcb6756" type="application/pdf" title="VRTX_News_2014_7_10_General.pdf">Vertex Announces Retirement of Peter Mueller, Ph.D.</a></span><span class="filesize"> 11.9 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-06-30T20:05:00Z" timezone="America/New_York" class="datetime">Jun 30, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-submits-supplemental-new-drug-application-snda-us-food" hreflang="en">Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for Use of KALYDECO® (ivacaftor) in People 18 and Older with Cystic Fibrosis who have the R117H Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Marketing Authorization Application (MAA) variation in Europe planned for third quarter of 2014- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-submits-supplemental-new-drug-application-snda-us-food" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/41aabddf-c57d-4e6d-ac94-8d9d5854c0be" type="application/pdf" title="VRTX_News_2014_6_30_General.pdf">Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for Use of KALYDECO&#174; (ivacaftor) in People 18 and Older with Cystic Fibrosis who have the R117H Mutation</a></span><span class="filesize"> 26.8 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-06-27T11:14:00Z" timezone="America/New_York" class="datetime">Jun 27, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-european-chmp-positive-opinion-kalydecotm" hreflang="en">Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -In Europe, approximately 250 people ages 6 and older have one of 8 additional gating mutations- -KALYDECO is the first medicine to treat the underlying cause of CF in people with non-G551D gating mutations- EYSINS, Switzerland --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-european-chmp-positive-opinion-kalydecotm" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/f6aa89ac-2d10-40bf-bb7a-0ecbb81571b3" type="application/pdf" title="VRTX_News_2014_6_27_General.pdf">Vertex Receives European CHMP Positive Opinion for KALYDECO&#8482; (ivacaftor) in Eight Non-G551D Gating Mutations</a></span><span class="filesize"> 27.8 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-06-24T11:00:00Z" timezone="America/New_York" class="datetime">Jun 24, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/two-24-week-phase-3-studies-lumacaftor-combination-ivacaftor-met" hreflang="en">Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Combination of lumacaftor and ivacaftor is the first regimen designed to treat the underlying cause of CF in people with two copies of the F508del mutation, the most common form of the disease- -All four 24-week treatment arms achieved primary endpoint of mean absolute improvement in FEV 1
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/two-24-week-phase-3-studies-lumacaftor-combination-ivacaftor-met" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/74bd0e19-4a50-468e-88ea-814e515d13bc" type="application/pdf" title="VRTX_News_2014_6_24_General.pdf">Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation</a></span><span class="filesize"> 104.5 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-06-18T12:30:00Z" timezone="America/New_York" class="datetime">Jun 18, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-licenses-vx-787-janssen-pharmaceuticals-treatment" hreflang="en">Vertex Licenses VX-787 to Janssen Pharmaceuticals for the Treatment of Influenza</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -VX-787 is an investigational medicine discovered by Vertex that is designed to directly inhibit replication of the influenza virus- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into a licensing agreement with Janssen
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4041&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Other</small></a>
  </div>
    </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-licenses-vx-787-janssen-pharmaceuticals-treatment" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/7cad3698-c0e7-40b5-aa73-6808f2bf182e" type="application/pdf" title="VRTX_News_2014_6_18_General.pdf">Vertex Licenses VX-787 to Janssen Pharmaceuticals for the Treatment of Influenza</a></span><span class="filesize"> 21.3 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-06-16T21:15:00Z" timezone="America/New_York" class="datetime">Jun 16, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-signed-letter-intent-enable-public" hreflang="en">Vertex Announces a Signed Letter of Intent to Enable Public Reimbursement of KALYDECO® (ivacaftor) in Canada for Eligible People with Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Before patients can get access through public reimbursement, each participating province or territory must decide to reimburse KALYDECO through its individual drug program- -Approximately 100 people ages 6 and older in Canada have the G551D mutation - BOSTON --(BUSINESS WIRE)-- Vertex
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-signed-letter-intent-enable-public" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/472034fa-c5c5-4501-ae8c-f3ce5dee85f6" type="application/pdf" title="VRTX_News_2014_6_16_General.pdf">Vertex Announces a Signed Letter of Intent to Enable Public Reimbursement of KALYDECO&#174; (ivacaftor) in Canada for Eligible People with Cystic Fibrosis</a></span><span class="filesize"> 27.6 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-06-12T13:00:00Z" timezone="America/New_York" class="datetime">Jun 12, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-presentation-new-kalydecotm-ivacaftor-data" hreflang="en">Vertex Announces Presentation of New KALYDECO™ (ivacaftor) Data at European Cystic Fibrosis Society Conference</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -New data showed that KALYDECO reduced the loss of lung function by half over 3 years in people with CF who have the G551D mutation compared to similar untreated patients- -New data from rollover study of ivacaftor in people with the R117H mutation support earlier results from Phase 3 study that
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-presentation-new-kalydecotm-ivacaftor-data" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/512a19a8-cad8-4f33-a859-1a77340e37a4" type="application/pdf" title="VRTX_News_2014_6_12_General.pdf">Vertex Announces Presentation of New KALYDECO&#8482; (ivacaftor) Data at European Cystic Fibrosis Society Conference</a></span><span class="filesize"> 33.3 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-06-04T12:00:00Z" timezone="America/New_York" class="datetime">Jun 4, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/proof-concept-study-ivacaftor-monotherapy-showed-improvements" hreflang="en">Proof-of-Concept Study of Ivacaftor Monotherapy Showed Improvements in Lung Function After Two Weeks of Treatment in People with Cystic Fibrosis who have a Residual Function Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Data are consistent with in vitro observations in residual function mutations showing that ivacaftor improved CFTR activity- -8-week open-label period showed improvements in lung function- -Data support plans to initiate a Phase 3 study of ivacaftor in people with CF who have a residual function
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/proof-concept-study-ivacaftor-monotherapy-showed-improvements" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/bb0f75ed-b132-42cc-a285-53a2c1a78dbe" type="application/pdf" title="VRTX_News_2014_6_4_General.pdf">Proof-of-Concept Study of Ivacaftor Monotherapy Showed Improvements in Lung Function After Two Weeks of Treatment in People with Cystic Fibrosis who have a Residual Function Mutation</a></span><span class="filesize"> 35.1 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-06-03T20:01:00Z" timezone="America/New_York" class="datetime">Jun 3, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-goldman-sachs-global-healthcare-conference-june" hreflang="en">Vertex to Present at the Goldman Sachs Global Healthcare Conference on June 10</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 10 at 11:00 a.m. ET . Management&#039;s remarks can be accessed live through Vertex&#039;s website at www.vrtx.com in the
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-goldman-sachs-global-healthcare-conference-june" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/37593f64-9e85-4e2f-9bc6-2a633d32a118" type="application/pdf" title="VRTX_News_2014_6_3_Webcasts.pdf">Vertex to Present at the Goldman Sachs Global Healthcare Conference on June 10</a></span><span class="filesize"> 9.2 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-05-13T20:01:00Z" timezone="America/New_York" class="datetime">May 13, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-ubs-global-healthcare-conference-may-20" hreflang="en">Vertex to Present at the UBS Global Healthcare Conference on May 20</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the UBS Global Healthcare Conference on Tuesday, May 20 at 11:00 a.m. ET . The audio portion of the remarks will be accessible live through Vertex&#039;s website at www.vrtx.com in the
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-ubs-global-healthcare-conference-may-20" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/2cab1e76-ab46-4f8e-9a70-f559345af215" type="application/pdf" title="VRTX_News_2014_5_13_Webcasts.pdf">Vertex to Present at the UBS Global Healthcare Conference on May 20</a></span><span class="filesize"> 9.2 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-05-07T20:05:00Z" timezone="America/New_York" class="datetime">May 7, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/william-young-joins-vertex-board-directors" hreflang="en">William Young Joins Vertex Board of Directors</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that William Young joined its board of directors as an independent director. Mr. Young was elected to the class of directors whose term expires in 2017. The Vertex board now consists of 10 members. &quot;Mr.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/william-young-joins-vertex-board-directors" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/9f12102d-c7d9-4569-b155-34d5ff2ff761" type="application/pdf" title="VRTX_News_2014_5_7_General.pdf">William Young Joins Vertex Board of Directors</a></span><span class="filesize"> 10.2 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-05-01T20:02:00Z" timezone="America/New_York" class="datetime">May 1, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/addition-vx-661-kalydecor-ivacaftor-improves-lung-function" hreflang="en">Addition of VX-661 to KALYDECO® (ivacaftor) Improves Lung Function in People with CF Who Are Heterozygous for the F508del and G551D Mutations in 28-day Phase 2 Proof-of-Concept Study</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Data provide proof-of-concept for use of VX-661 to further enhance CFTR function in people taking KALYDECO who have the F508del mutation and another mutation known to respond to KALYDECO alone- -Statistically significant improvements in lung function, as well as decreases in sweat chloride,
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/addition-vx-661-kalydecor-ivacaftor-improves-lung-function" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/5db5b8f8-33ad-4b27-b299-bae77e7c177e" type="application/pdf" title="VRTX_News_2014_5_1_General.pdf">Addition of VX-661 to KALYDECO&#174; (ivacaftor) Improves Lung Function in People with CF Who Are Heterozygous for the F508del and G551D Mutations in 28-day Phase 2 Proof-of-Concept Study</a></span><span class="filesize"> 68.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2014-05-01T20:01:00Z" timezone="America/New_York" class="datetime">May 1, 2014</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-first-quarter-2014-financial-results-and-provides" hreflang="en">Vertex Reports First Quarter 2014 Financial Results and Provides Updates on Key Business Priorities</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Net product revenues of $100 million for KALYDECO in cystic fibrosis- -Cash, cash equivalents and marketable securities of $1.32 billion on March 31, 2014 - -Six-month dosing period complete for Phase 3 TRAFFIC and TRANSPORT studies of lumacaftor in combination with ivacaftor for people with CF
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4011&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Cystic Fibrosis</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-first-quarter-2014-financial-results-and-provides" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/5db5b8f8-33ad-4b27-b299-bae77e7c177e" type="application/pdf" title="VRTX_News_2014_5_1_General.pdf">Vertex Reports First Quarter 2014 Financial Results and Provides Updates on Key Business Priorities</a></span><span class="filesize"> 68.4 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
      </tbody>
</table>

    </div>
  
        <nav class="pager" role="navigation" aria-labelledby="pagination-heading">
    <h4 id="pagination-heading" class="visually-hidden">Pagination</h4>
    <ul class="pager__items js-pager__items">
                    <li class="pager__item pager__item--first">
          <a href="?items_per_page_toggle=1&amp;page=0" title="Go to first page">
            <span class="visually-hidden">First page</span>
            <span aria-hidden="true">First</span>
          </a>
        </li>
                          <li class="pager__item pager__item--previous">
          <a href="?items_per_page_toggle=1&amp;page=7" title="Go to previous page" rel="prev">
            <span class="visually-hidden">Previous page</span>
            <span aria-hidden="true">Previous</span>
          </a>
        </li>
                          <li class="pager__item pager__item--ellipsis" role="presentation" aria-hidden="true">&hellip;</li>
                          <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=7" title="Go to page 8">
            <span class="visually-hidden">
              Page
            </span>8</a>
        </li>
              <li class="pager__item is-active">
                                          <a href="?items_per_page_toggle=1&amp;page=8" title="Current page" aria-current="page">
            <span class="visually-hidden">
              Current page
            </span>9</a>
        </li>
              <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=9" title="Go to page 10">
            <span class="visually-hidden">
              Page
            </span>10</a>
        </li>
              <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=10" title="Go to page 11">
            <span class="visually-hidden">
              Page
            </span>11</a>
        </li>
                          <li class="pager__item pager__item--ellipsis" role="presentation" aria-hidden="true">&hellip;</li>
                          <li class="pager__item pager__item--next">
          <a href="?items_per_page_toggle=1&amp;page=9" title="Go to next page" rel="next">
            <span class="visually-hidden">Next page</span>
            <span aria-hidden="true">Next</span>
          </a>
        </li>
                          <li class="pager__item pager__item--last">
          <a href="?items_per_page_toggle=1&amp;page=16" title="Go to last page">
            <span class="visually-hidden">Last page</span>
            <span aria-hidden="true">Last</span>
          </a>
        </li>
          </ul>
  </nav>

  
          <div class="view-footer">
          <div class="results-summary">Displaying 401 - 450 of 836 results</div>
        </div>
    </div>
</div>

  </div>
</div>
        </div>
      </div>
    </div>
  </div>

</div><!-- /.boxton -->

  </div>
</article>

  </div>

  </div>

                </div>
            

            


            <footer>
                                <div class="column footer-sitemap">
                    <div class="row small-up-1 medium-up-4 large-up-4 flexy">
                        

<div role="navigation" aria-labelledby="block-footercol1-menu" id="block-footercol1" class="block--system-menu-blockfooter-col-1 block--system-menu-blockfooter-col-1--5816 block--footer-first--system-menu-block--footer-col-1 block--footer-first--system-menu-block--footer-col-1--5816 block--da449755-c1be-4e93-bf75-4db21af16447 block--da449755-c1be-4e93-bf75-4db21af16447--5816 block block-menu navigation block-system-menublock menu--footer-col-1 small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-footercol1-menu" class="lead">Footer Col 1</p>
    

                              <ul data-block-uuid="da449755-c1be-4e93-bf75-4db21af16447" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="/press-releases" target="" rel="" data-drupal-link-system-path="node/5816">News &amp; Events</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/stock-information" target="" rel="" data-drupal-link-system-path="node/5916">Stock Information</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/stock-information/analyst-coverage" target="" rel="" data-drupal-link-system-path="node/5896">Analyst Coverage</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-footercol2-menu" id="block-footercol2" class="block--system-menu-blockfooter-col-2 block--system-menu-blockfooter-col-2--31451 block--footer-first--system-menu-block--footer-col-2 block--footer-first--system-menu-block--footer-col-2--31451 block--bdf059f5-091d-492a-8531-746af0f478ff block--bdf059f5-091d-492a-8531-746af0f478ff--31451 block block-menu navigation block-system-menublock menu--footer-col-2 small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-footercol2-menu" class="lead">Footer Col 2</p>
    

                              <ul data-block-uuid="bdf059f5-091d-492a-8531-746af0f478ff" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="/financial-information/quarterly-results" target="" rel="" data-drupal-link-system-path="node/5986">Financial Information</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Corporate Governance</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">Investor Resources</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-footercol3-menu" id="block-footercol3" class="block--system-menu-blockfooter-col-3 block--system-menu-blockfooter-col-3--31451 block--footer-first--system-menu-block--footer-col-3 block--footer-first--system-menu-block--footer-col-3--31451 block--7e76016d-878b-43d2-a4f3-4289a342a22d block--7e76016d-878b-43d2-a4f3-4289a342a22d--31451 block block-menu navigation block-system-menublock menu--footer-col-3 small-6 large-3 columns">
            
    <p id="block-footercol3-menu" class="lead">Vertex Websites</p>
    

                              <ul data-block-uuid="7e76016d-878b-43d2-a4f3-4289a342a22d" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.com/">Global</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.fr/">France</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.de/">Germany</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.ca/">Canada</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtxpharma.co.uk/">United Kingdom</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.com/en-us">United States</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-socialmedia-menu" id="block-socialmedia" class="block--system-menu-blocksocial-media block--system-menu-blocksocial-media--31451 block--footer-first--system-menu-block--social-media block--footer-first--system-menu-block--social-media--31451 block--5d1642a9-9f5b-4bed-9f56-6157a76875d1 block--5d1642a9-9f5b-4bed-9f56-6157a76875d1--31451 block block-menu navigation block-system-menublock menu--social-media small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-socialmedia-menu" class="lead">Social Media</p>
    

                              <ul data-block-uuid="5d1642a9-9f5b-4bed-9f56-6157a76875d1" class="menu vertical">
                                                                                              <li class="isSocialLink side-menu__item">
                            <a href="https://www.facebook.com/VertexPharmaInc" class="facebook" aria-label="facebook">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-facebook fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://www.linkedin.com/company/vertex-pharmaceuticals" class="linkedin" aria-label="linkedin">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-linkedin fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://twitter.com/VertexPharma" class="x-twitter" aria-label="x-twitter">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-x-twitter fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://www.youtube.com/channel/UCrNu_QIE9exwVQnWKgr1toQ/featured" class="youtube" aria-label="youtube">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-youtube fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
          </ul>
  


    </div>

                    </div>
                </div>
                                <div class="column primary footer-global">
                    <div class="row">
                                                <div class="medium-6 columns">
                                                        <div class="region region-footer">
                                <nav role="navigation" aria-labelledby="block-footerbottom-menu" class="block--system-menu-blockfooter-bottom block--system-menu-blockfooter-bottom--5986 block--footer--system-menu-block--footer-bottom block--footer--system-menu-block--footer-bottom--5986 block--e172c75d-9834-4259-9057-aa69edfb5161 block--e172c75d-9834-4259-9057-aa69edfb5161--5986 block block-menu navigation block-system-menublock menu--footer-bottom">
                                    <ul data-block-uuid="e172c75d-9834-4259-9057-aa69edfb5161" class="menu side-menu">
                                        <li class="side-menu__item">
                                            <a href="https://www.vrtx.com/international-privacy" target="_blank">Privacy Policy</a>
                                        </li>
                                        <li class="side-menu__item">
                                            <a href="https://www.vrtx.com/terms-and-conditions" target="_blank">Terms of Use</a>
                                        </li>
                                        <li class="side-menu__item">
                                            <!-- OneTrust Cookies Settings button start -->
                                            <a id="ot-sdk-btn" class="ot-sdk-show-settings">Your Privacy Choices</a>
                                            <!-- OneTrust Cookies Settings button end -->
                                        </li>
                                        <li>
                                            <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/images/privacyoptions.svg" style="width:25px">
                                        </li>
                                    </ul>
                                </nav>
                            </div>
                        </div>
                        
                        <div class="medium-6 columns">
                            <ul class="menu float-right">
                                <li class="menu-text">Copyright &copy; 2025</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </footer>


        </div> <!-- /off-canvas-content -->

        <div class="js-off-canvas-exit"></div>


    </div> <!-- /off-canvas-wrapper-inner -->
</div> <!-- /off-canvas-wrapper -->
  </div>

    
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/5816","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","currentQuery":{"items_per_page_toggle":"1","page":"8"}},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyVUlFuwzAIvVAUa_3ZAXaCaQewiI06VhsqIG1z-zpOpa1TN22yhB_P8IzBTBonMAzcACVhG_gr5SJlAu1kOmAmF40ZvK2poIVP2EMq6AG9B8SpSDoEYCiLeVRw4n0TbjrvoP6ncItd-4fYisBRMUmtyI0n4V-1H7Ljmg6c_5Vj3uzrLH4rbS5OtTUHwr3bT4-w33q5ghE-4BIh55gKmEUoqL717kh59_S8C3JCVcqbdL9pe1X45m9VvKzwzZfS2tUzzjgZOUYWp9Qm9IAbb_ugkOkSCywyu4U7b7A2Bqxh_QnDifBsoduxSp4LXgFrIOEu","theme":"nir_pid2172","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"user":{"uid":0,"permissionsHash":"45e7a25462df2b241c7eec49f3c8a237acab787c5b520da38b10415af90811be"}}</script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/jquery-2.1.4.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/jquery.circliful.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/theme-embedded.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/ndq-functions.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/foundation.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/vivus.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/theme-embedded-2.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/js/modal-video.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/js/modal-video.run.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_yoTi3ajw4iS9VMtHeeJMhx7zxXd9S5AacrChSDHVlFQ.js?scope=footer&amp;delta=9&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>
<script src="/core/assets/vendor/ckeditor5/ckeditor5-dll/ckeditor5-dll.js?v=41.3.1"></script>
<script src="/profiles/nasdaqir/modules/custom/nir_ckeditor_datatables/js/build/datatables.js?v=1.10.9"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_GZWqVv5lmgvMD-78CCnz6GUVTpAe1Qj92_PpS3CTNZA.js?scope=footer&amp;delta=12&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>

    <!-- Adobe Omniture JS Rewrite -->
<script type="text/plain" class="optanon-category-C0004">var s_CCSWebHostingAccount = "trcgvertex";</script>
<script src="//assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" type="text/plain" class="optanon-category-C0004"></script>
  </body>
</html>
